熱門資訊> 正文
Verrica Pharmaceuticals宣布5000万美元PIPE融资
2025-11-24 21:40
- Verrica Pharmaceuticals (VRCA) said it has signed securities purchase agreements for a private investment in public equity (PIPE) that will raise about $50 million in gross proceeds before fees.
- The financing is expected to close around November 25, 2025, pending standard closing conditions.
- Under the securities purchase agreements, Verrica will sell 6,499,826 common shares and/or pre-funded warrants for 5,305,164 shares, along with Series C warrants to buy 2,951,241 shares, at a combined price of $4.24125 per share of common stock and accompanying Series C warrant.
- Verrica (VRCA) plans to use $35 million from the PIPE’s initial closing to fully repay and terminate its credit agreement with OrbiMed. The remaining funds will go toward working capital and general corporate needs. With the PIPE proceeds and its current cash, the company expects to be funded through mid-2027.
- VRCA +3.5% premarket to $4.3603
- Source: Press Release
More on Verrica Pharmaceuticals
- Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript
- Verrica targets European expansion for YCANTH as Phase III programs advance and sales force grows
- Seeking Alpha’s Quant Rating on Verrica Pharmaceuticals
- Historical earnings data for Verrica Pharmaceuticals
- Financial information for Verrica Pharmaceuticals
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。